Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today the acceptance of
nine abstracts at the 2022 American College of Rheumatology’s (ACR)
annual meeting, ACR Convergence 2022, being held November 10-14,
2022, at the Pennsylvania Convention Center in Philadelphia,
Pennsylvania.
Selected as a Featured Poster and ACR’s Ignite Talk
is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial
Intelligence Accurately Predicts Early Rheumatoid Arthritis
Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response
Rates and Enabling Early Identification of Patients Requiring
Subsequent Biological Therapy,” part of the core technology
powering Exagen’s AVISE® RADR test development. In addition, data
from Exagen’s research on machine learning in patients with
fibromyalgia has been accepted for an oral presentation.
Exagen’s President and Chief Executive Officer, Ron
Rocca, shared, “Exagen is honored to have nine scientific abstracts
accepted for ACR’s 2022 annual conference, with a featured poster
focusing on AVISE® RADR and a podium presentation. We continue to
assist physicians by adding clarity to their clinical diagnoses by
providing precision testing; we believe good science leads to good
decisions.”
Below is the list of accepted abstracts, with links
to each:
Saturday, November 12, 2022
Poster Presentation | Presented by Geoffrey
Stephens, PhD | Abstract #0324 Title: Comparison of nCounter® and
BioFire® Technologies for the Measurement of Type I Interferon
SignatureSession Title: SLE – Diagnosis, Manifestations, and
Outcomes Poster I: Diagnosis Session Time: 1:00 – 3:00pm ET
Sunday, November 13, 2022
Featured Poster Presentation | Presented by Giorgio
Casaburi, PhD | Abstract #0935 Title: Targeted Synovial Tissue
RNA-Seq Coupled with Artificial Intelligence Accurately Predicts
Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs,
Enriching csDMARDs Response Rates and Enabling Early Identification
of Patients Requiring Subsequent Biological TherapySession Title:
RA – Treatment Poster II Session Time: 9:00 – 10:30am ET
Poster Presentation | Presented by Anca Askanase,
MD | Abstract #1442 Title: Role of Platelet-bound Complement
Activation Product (PC4d) in Predicting Risk of Future Thrombotic
Events in Systemic Lupus ErythematosusSession Title: SLE –
Diagnosis, Manifestations, and Outcomes Poster II: Manifestations
Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Mark Rudolph,
PhD | Abstract #1221 Title: Multi-Center Validation of Cell-Bound
Complement Activation Products and a Multianalyte Assay Panel
Distinguishing Systemic Lupus Erythematosus from Primary
Fibromyalgia Session Title: Fibromyalgia and Other Clinical Pain
Syndromes Poster Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Emily G Oaks |
Abstract #1201 Title: Autoimmune Serologies, Cell-Bound Complement
Activation Products, and Autoimmune Rheumatic Disease Symptoms
after COVID-19 InfectionSession Title: Epidemiology and Public
Health Poster II Session Time: 1:00 – 3:00pm ET
Monday, November 14, 2022
Poster Presentation | Presented by Mark Rudolph,
PhD | Abstract #1762 Title: Stability of Cell Bound Complement
Activation Products (CB-CAPS), Multianalyte Assay Panel (MAP) with
Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients
Throughout the SARS-COV-2 Pandemic and Vaccination CampaignsSession
Title: Epidemiology and Public Health Poster III Session Time: 1:00
– 3:00pm ET
Poster Presentation | Presented by Giorgio
Casaburi, PhD | Abstract #1990 Title: Artificial Intelligence
Applied to Transcriptomics Profiling of Synovial Tissue Biopsies
Accurately Predicts Rheumatoid Arthritis Patients who will Respond
or be Refractory to Standard Biological TreatmentsSession Title: RA
– Treatment Poster IVSession Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Jennifer Rogers,
MD | Abstract #2104 Title: The Use of Cell-bound Complement
Activation Product to Assess Disease Activity in SLE.Session Title:
SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes
Session Time: 1:00 – 3:00pm ET
Oral Presentation | Presented by Geoffrey Stephens,
PhD | Abstract #2233 Title: Machine Learning Uncovers Novel mRNAs
Expressed in Fibromyalgia Session Title: Abstracts: Fibromyalgia
and Other Clinical Pain Syndromes Session Time: 4:30 – 5:30pm
ET
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of
autoimmune diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE® testing and is
investing in its product pipeline to support patients throughout
their autoimmune diagnosis and treatment journeys. The goal
at Exagen is to assist patients, physicians, and payors
by enabling precision medicine. Exagen is located
in San Diego County with clinical and research and
development laboratories in Vista, CA.
For more information, please
visit Exagen.com and follow @ExagenInc on
Twitter.
Forward Looking Statements
Exagen cautions you that statements contained
in this press release regarding matters that are not historical
facts are forward-looking statements. These statements are based on
Exagen’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
our clinical research and development team’s scientific abstracts
for presentation at ACR Annual Conference and the potential to lead
to increased adoption of any AVISE® test. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: the COVID-19
pandemic may continue to adversely affect its business, financial
condition and results of operations, including as a result of
slowdown in its operations as well as those of its suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests causing an
increase in cost per test, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third-party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
expectations regarding its pipeline products, including the
development of the AVISE® RADR platform; Exagen’s ability to obtain
and maintain intellectual property protection for its testing
products; regulatory developments affecting Exagen’s business; and
other risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange
Commission (“SEC”), including under the heading “Risk Factors”
in Exagen’s Annual Report on Form 10-K for the year
ended December 31, 2021 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi,
Chief Financial Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024